Evaluation of angiogenic factors in prediction of growth‐related neonatal morbidity at term and comparison with competing‐risks model
Ultrasound in Obstetrics & Gynecology · 2024
DOI: 10.1002/uog.27533 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Ultrasound in Obstetrics & Gynecology, 2024. Verfasst von I Papastefanou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women and Children's Health, School of Life Course and Population Sciences, Faculty of Life Sciences & Medicine, King's College London,…. Hauptthemen laut MEDLINE: Ultrasonography, Prenatal, Fetal Growth Retardation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Fetal Medicine Foundation.
Abstract (Originalsprache)
Objectives
First, to describe the distribution of biomarkers of impaired placentation in small‐for‐gestational‐age (SGA) pregnancies with neonatal morbidity; second, to examine the predictive performance for growth‐related neonatal morbidity of a high soluble fms‐like tyrosine kinase‐1 (sFlt‐1)/placental growth factor (PlGF) ratio or low PlGF; and, third, to compare the performance of a high sFlt‐1/PlGF ratio or low PlGF with that of the competing‐risks model for SGA in predicting growth‐related neonatal morbidity.
Methods
This was a prospective observational study of women attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation in two maternity hospitals in England. The visit included recording of maternal demographic characteristics and medical history, an ultrasound scan and measurement of serum PlGF and sFlt‐1. The primary outcome was delivery within 4 weeks after assessment and at < 42 weeks' gestation of a SGA neonate with birth weight < 10 th or < 3 rd percentile, combined with neonatal unit (NNU) admission for ≥ 48 h or a composite of major neonatal morbidity. The detection rates in screening by PlGF < 10 th percentile, sFlt‐1/PlGF ratio > 90 th percentile, sFlt‐1/PlGF ratio > 38 and the competing‐risks model for SGA, using combinations of maternal risk factors and Z ‐scores of estimated fetal weight (EFW) with multiples of the median values of uterine artery pulsatility index, PlGF and sFlt‐1, were estimated. The detection rates by the different methods of screening were compared using McNemar's test.
Results
In the study population of 29 035 women, prediction of growth‐related neonatal morbidity at term provided by the competing‐risks model was superior to that of screening by low PlGF concentration or a high sFlt‐1/PlGF concentration ratio. For example, at a screen‐positive rate (SPR) of 13.1%, as defined by the sFlt‐1/PlGF ratio > 38, the competing‐risks model using maternal risk factors and EFW predicted 77.5% (95% CI, 71.7–83.3%) of SGA < 10 th percentile and 89.3% (95% CI, 83.7–94.8%) of SGA < 3 rd percentile with NNU admission for ≥ 48 h delivered within 4 weeks after assessment. The respective values for SGA with major neonatal morbidity were 71.4% (95% CI, 56.5–86.4%) and 90.0% (95% CI, 76.9–100%). These were significantly higher than the respective values of 41.0% (95% CI, 34.2–47.8%) ( P < 0.0001), 48.8% (95% CI, 39.9–57.7%) ( P < 0.0001), 37.1% (95% CI, 21.1–53.2%) ( P = 0.003) and 55.0% (95% CI, 33.2–76.8%) ( P = 0.035) achieved by the application of the sFlt‐1/PlGF ratio > 38. At a SPR of 10.0%, as defined by PlGF < 10 th percentile, the competing‐risks model using maternal factors and EFW predicted 71.5% (95% CI, 65.2–77.8%) of SGA < 10 th percentile and 84.3% (95% CI, 77.8–90.8%) of SGA < 3 rd percentile with NNU admission for ≥ 48 h delivered within 4 weeks after assessment. The respective values for SGA with major neonatal morbidity were 68.6% (95% CI, 53.1–83.9%) and 85.0% (95% CI, 69.4–100%). These were significantly higher than the respective values of 36.5% (95% CI, 29.8–43.2%) ( P < 0.0001), 46.3% (95% CI, 37.4–55.2%) ( P < 0.0001), 37.1% (95% CI, 21.1–53.2%) ( P = 0.003) and 55.0% (95% CI, 33.2–76.8%) ( P = 0.021) achieved by the application of PlGF < 10 th percentile.
Conclusion
At 36 weeks' gestation, the prediction of growth‐related neonatal morbidity by the competing‐risks model for SGA, using maternal risk factors and EFW, is superior to that of a high sFlt‐1/PlGF ratio or low PlGF. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Women and Children's Health, School of Life Course and Population Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
- Fetal Medicine Research Institute, King's College Hospital, London, UK.
ORCID-Profile: I Papastefanou, A Syngelaki
Förderung
- Fetal Medicine Foundation
Zitieren
APA
Papastefanou, I., Nobile Recalde, A., Silva Souza, Y., Syngelaki, A., & Nicolaides, K. H. (2024). Evaluation of angiogenic factors in prediction of growth‐related neonatal morbidity at term and comparison with competing‐risks model. Ultrasound in Obstetrics & Gynecology. https://doi.org/10.1002/uog.27533
Vancouver
Papastefanou I, Nobile Recalde A, Silva Souza Y, Syngelaki A, Nicolaides KH. Evaluation of angiogenic factors in prediction of growth‐related neonatal morbidity at term and comparison with competing‐risks model. Ultrasound in Obstetrics & Gynecology. 2024. doi:10.1002/uog.27533
BibTeX
@article{Papastefanou2024,
author = {Papastefanou, I and Nobile Recalde, A and Silva Souza, Y and Syngelaki, A and Nicolaides, K H},
title = {Evaluation of angiogenic factors in prediction of growth‐related neonatal morbidity at term and comparison with competing‐risks model},
journal = {Ultrasound in Obstetrics & Gynecology},
year = {2024},
doi = {10.1002/uog.27533}
}
EUVIMED